Table 1.

Literature reporting health outcomes for COVID-19 infection in patients with amyloidosis.

Author, Year	Study Period	Cohort and Subgroups	Location of Study	Vaccination Rate	COVID-19 Infection Rate	Clinical Outcomes
Wood et al., 2020 [15]	April–July 2020	Hematological malignancy with COVID-19 250 pts), of which 40 pts (16%) had MM or AL	Worldwide (65% in North America)	N/A	N/A	30/37 (81.1%) with moderate to severe infection, 11/39 (28% mortality)
Lewis et al., 2022 [16]	January 2020–April 2022	ATTR (152 pts) and AL (103 pts)	Alberta, Canada	ATTR 137/152 (90.6%) vaccinated. AL 84/103 (81.6%) vaccinated.	ATTR 78/131 (59.5%) tested 4/78 (5.1%) PCR +ve AL 42/60 (70%) tested 11/42 (26.2%) PCR +ve 6/15 (40%) PCR +ve patients were unvaccinated	4 patients required hospital admission (2 AL patients both vaccinated; 2 ATTR patients both unvaccinated) 1 death caused directly by COVID-19 infection (ATTR patient, not vaccinated)
Ho et al., 2023 [17]	January 2020–August 2021	MM and AL (9225 pts)	United States	187/9225 (2%) (174 MM.; 13AL)	187/9225 (2%) (174 MM.; 13 AL)	3/13 (23.1%) with severe infection, 4/13 (30.8%) required hospital admission, 1/13 (7.8%) required ICU admission, 9 patient deaths (9 MM.; 0 AL) 2 patients (17%) with severe infection; 0 deaths